Dyadic International (DYAI) Net Income towards Common Stockholders Growth (5y) (2023 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Income towards Common Stockholders Growth (5y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 77.48% |
| Dec 31, 2025 | 4.96% |
| Sep 30, 2025 | 4.87% |
| Jun 30, 2025 | 7.77% |
| Mar 31, 2025 | 1.98% |
| Dec 31, 2024 | 2.71% |
| Sep 30, 2024 | 37.34% |
| Jun 30, 2024 | 5.86% |
| Mar 31, 2024 | 1.09% |
| Dec 31, 2023 | -32.24% |
| Sep 30, 2023 | -0.95% |
| Jun 30, 2023 | -6.44% |
| Mar 31, 2023 | 0.97% |